Neuroprotective effects of delayed administration of growth/ differentiation factor-5 in the partial lesion model of Parkinson's disease

Experimental Neurology

Volumn 185, Issue 2, 2004, Pages 281-289

  Hurley, Fiona M ^a   Costello, Daniel J ^a   Sullivan, Aideen M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

6 Hydroxydopamine; Dopamine; GDF 5; Neurodegeneration; Neuroregeneration; Parkinson's disease; Rat

Indexed keywords

AMPHETAMINE; GROWTH FACTOR; NEUROTROPHIN 4; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOCYTOCHEMISTRY; LOCOMOTION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0346373878     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.10.003     Document Type: Article

References (26)

1. Aoi M., Date I., Tomita S., Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci. Res. 36:2000;319-325.
2. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.-C.E. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
3. Bowenkamp K.E., Lapchak P.A., Hoffer B.J., Bickford P.C. Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Neurosci. Lett. 211:1996;81-84.
4. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.-F.H., Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
5. Hoffman A.F., van Horne C.G., Eken S., Hoffer B.J., Gerhardt G.A. In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp. Neurol. 147:1997;130-141.
6. Hotten G., Neidhardt H., Jacobowsky B., Pohl J. Cloning and expression of recombinant human growth/differentiation factor 5. Biochem. Biophys. Res. Comm. 204:1994;646-652.
7. Howard C.V., Reed M.G. Unbiased Stereology. 1998;Bios Scientific Publishers, Oxford, UK.
8. Ichitani Y., Okamura Y., Masamoto I., Nagatsu I., Abata Y. Degeneration of nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum. Brain Res. 549:1991;350-353.
9. Ichitani Y., Okamura H., Nakahara D., Nagatsu I., Ibata Y. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp. Neurol. 130:1994;269-278.
10. Kirik D., Georgievska B., Rosenblad C., Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 13:2001;1589-1599.
11. Krieglstein K., Suter-Crazzolara C., Hotten G., Pohl J., Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-b superfamily, on midbrain dopaminergic neurons. J. Neurosci. Res. 42:1995;724-732.
12. Lapchak P.A., Miller P.J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience. 78:1997;61-72.
13. Mayhew T.M. A review of recent advances in stereology for quantifying neural structure. J. Neurocytol. 21:1992;313-328.
14. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1988;Academic Press, San Diego, USA.
15. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
16. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience. 82:1998;129-137.
17. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11:1999;1554-1566.
18. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161:2000;503-516.
19. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
20. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad Sci. U.S.A. 92:1995;8935-8939.
21. Sullivan A.M., Opacka-Juffry J., Hotten G., Pohl J., Blunt S.B. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neurosci. Letts. 233:1997;73-76.
22. Sullivan A.M., Pohl J., Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur. J. Neurosci. 10:1998;3681-3688.
23. Sullivan A.M., Opacka-Juffiy J., Pohl J., Blunt S.B. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res. 818:1999;176-179.
24. Tomac A., Lindqvist E., Lin L.-F.H., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
25. Tomac A., Widenfalk J., Lin L.-F.H., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests atrophic role in the adult. Proc. Natl. Acad Sci. U.S.A. 92:1995;8274-8278.
26. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16:1996;7206-7215.